Research Topics
| Martin S WeberSummaryAffiliation: Klinikum rechts der Isar Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effectsMartin S Weber
Department of Neurology, Technische Universitat Munchen, Munich, Germany
Curr Pharm Des 18:209-19. 2012..In this review, we aim to critically evaluate the risk/benefit ratio of therapeutic strategies in treatment of MS with a specific focus on infectious neurological side effects...
Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune diseaseMartin S Weber
Department of Neurology, Technische Universitat Munchen, Munich, Germany
PLoS ONE 5:e16009. 2010..Besides its therapeutic implication, this finding suggests that encounter of the immune system with microbial products may not only be part of CNS autoimmune disease pathogenesis but also of its regulation...
Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell responseChristian L Seifert
Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
Mult Scler 18:1045-9. 2012..This delay in the development of a humoral immune response may reflect the step-wise B-cell colonization of the CNS and represent an attractive therapeutic window of opportunity...
The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon?Johann Sellner
Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
CNS Neurosci Ther 16:362-73. 2010..Moreover, we try to address the evident question whether usage of this combination routinely requires caution, since the number of IFN-β-treated MS patients receiving statins for lowering of cholesterol is expected to grow...
Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disordersKlaus Lehmann-Horn
Department of Neurology, Technische Universitat Munchen, Munich, Germany
J Neuroinflammation 8:146. 2011..We elucidated the regulatory role of un-activated B-cells in EAE and investigated whether anti-CD20 may collaterally diminish regulatory B-cell properties in treatment of neuroimmunological disorders...
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammationMarkus C Kowarik
Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, 81675 Munich, Germany
J Neuroinflammation 9:93. 2012....
Disease-modifying agents for multiple sclerosis: recent advances and future prospectsTil Menge
Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
Drugs 68:2445-68. 2008..Finally, with the advent of these highly potent novel therapies, rare, but potentially serious adverse effects have been noted, namely infections and malignancies. These are critically reviewed and put into perspective...
The role of antibodies in multiple sclerosisMartin S Weber
Department of Neurology, Technische Universität Müchen, Munich, Germany
Biochim Biophys Acta 1812:239-45. 2011....
Cooperation of B cells and T cells in the pathogenesis of multiple sclerosisMartin S Weber
Department of Neurology, Technische Universitat Munchen, Ismaningerstrasse 22, 81675, Munich, Germany
Results Probl Cell Differ 51:115-26. 2010..Taken together, B cells and T cells thus closely support one another to participate in the pathogenesis of MS in an inflammatory but also in a regulatory manner...
The value of the serum neurofilament protein heavy chain as a biomarker for peri-operative brain injury after carotid endarterectomyJohann Sellner
Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
Neurochem Res 34:1969-74. 2009....
